Start 30 days free, no card. Full Pro access for a month, then decide. Start free

Back to analysts list

Analyst

John Kilichowski

Wells Fargo · covers Real Estate

Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters).

Questions
31on tracked calls
Challenge rate
13%4 of 31 questions
Companies
5questioned at least once
Reporting periods
7with questions

These figures cover the whole profile: every tracked question, all reporting periods.

How to read these numbers

Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.

Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.

No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.

Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.

Small samples. Profiles with fewer than 10 questions are marked Limited sample.

Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.

Questions asked

Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.

Showing 31 of 31 questions from 5 companies

VTRVentas9 questions · 5 reporting periods · 2 of 9 challenging
VTR company page →

Calendar 2025 Q4

What does this imply in terms of U.S. growth? And then just overall, how much of this is just you capturing the opportunity in front of you

Revenue GrowthInnovation & R&DTranscript · FY2025 Q4 →
Show response

Hutchens cited US at 18% in 2025 as a proxy. Described 2025 actions: 12 new operators, 88 redevs, 26 transitions, 74 triple-net to SHOP conversions. OI platform execution and operator collaboration continuing to improve.

Could you walk us through the building blocks there and the assumptions, maybe there's some conservatism

Capital AllocationGuidance ReliabilityTranscript · FY2025 Q4 →
Show response

Probst explained 8% vs 10% gap: $0.04 Brookdale noncash amortization expiration + $2.2B debt refinancing at higher rates. G&A also growing with enterprise. These offsets explain the difference.

Calendar 2025 Q3

I'm just curious why that Same-Store NOI number is maybe a little lower than we would expect given the building blocks that you walked us through

ChallengingGeographic ExpansionMarginTranscript · FY2025 Q3 →
Show response

Hutchens said Canada has pricing limitations and Sunrise mix volatility. View Canada as high single-digit grower. US opportunity is better with less pricing limitations and stronger supply-demand.

Are there any near-term risks that you're monitoring that could possibly sort of uproot that thesis

M&ACapital AllocationTranscript · FY2025 Q3 →
Show response

Hutchens said no structural limitations, track record, platform, cost of capital, and momentum all working together for accelerating investment pace.

Calendar 2025 Q2

How could we think about that and back into what's a better run rate once this portfolio fully leases up

Show response

Hutchens confirmed 50% incremental margin from 80-90% occupancy, 70% from 90-100%. RevPOR growth 2x higher above 90% vs below (6-7% vs 3-5%).

I'm curious if you've done the work and can speak to the size of the addressable market, left out there today that is owned by the REITs

M&ACompetitive DynamicsTranscript · FY2025 Q2 →
Show response

Hutchens said REITs own ~15% of market, another 40-50% meets Ventas criteria. About $30B/year trades in senior housing, providing ample opportunity.

Calendar 2025 Q1

your cost per bed took a meaningful step up. I'm curious if that's to do with the competitive landscape or just where you're buying

ChallengingM&APricingTranscript · FY2025 Q1 →
Show response

Hutchens attributed step-up to newer vintage (~7yr avg), better markets (1,500bps uncapped net demand), quality operators. Cap rates compressing from 7% to 7.2% but still in 7-8% range.

Calendar 2024 Q4

How close are we in the cycle to having development really start to pencil? Like, what would RevPAR growth need to be in your models to get there

Competitive DynamicsCost PressureTranscript · FY2024 Q4 →
Show response

Hutchens said development is nowhere close to feasible, rents need 20-50% higher, no debt financing, barriers across land, material, and labor costs.

what deal flow looks like at this point right now versus maybe this time last year and the fourth quarter? And then maybe how the competitive environment is changing

M&ACompetitive DynamicsTranscript · FY2024 Q4 →
Show response

Hutchens confirmed pipeline is larger than prior year, cited competitive advantages in data analytics, operator relationships, and platform scale.

ORealty Income8 questions · 4 reporting periods · 2 of 8 challenging
O company page →

Calendar 2025 Q4

I feel like the AFFO guide was maybe below what the Street was expecting. I'm curious, where are the sources of conservatism in your guide?

ChallengingGuidance ReliabilityTranscript · FY2025 Q4 →
Show response

Pong identified the 40-50bp credit loss provision as the primary source of conservatism, noting the unidentified portion (majority) has low risk of being utilized.

Is that you moving into new verticals? Or -- and then how should we think about the yields on those?

Capital AllocationPricingTranscript · FY2025 Q4 →
Show response

Roy steered focus to spreads over cap rates, reiterating 150-155bp historical spread target on $8B, driven by strong pipeline across all geographies with no new product types.

Calendar 2025 Q3

There was the $0.03 of the termination fee that we've talked about. So what was the offsetting [ 2 ] to get you to plus 1

Guidance ReliabilityMarginTranscript · FY2025 Q3 →
Show response

Pong cited G&A, leasing commissions, unreimbursed property expenses, and record vacant dispositions as Q4 offsets to lease termination gains.

could you give us where your watch list stands today and then maybe how bad debt has performed relative to expectations

Show response

Roy confirmed watch list flat at 4.6% with granular 2bp median exposure, bad debt tracking to 75bp full-year guide with no changes.

Calendar 2025 Q2

there are a lot of portfolio deals expected to come to market in the second half of this year

Competitive DynamicsCapital AllocationTranscript · FY2025 Q2 →
Show response

Roy acknowledged growing competition from BlackRock, Starwood, JPMorgan and others but argued Realty Income's underwriting maturity and A-/A3 rating are advantages.

you reiterated the 75 bp credit loss guide. I was just hoping maybe you could talk about what you've experienced year-to-date

Show response

Pong confirmed $17M year-to-date reserves (65bp), reiterating 75bp with identified credits set aside plus unidentified cushion.

Calendar 2024 Q4

your provision for bad debt at seventy-five bps I want to say last year, you were closer to the thirty bp range

ChallengingCreditDemandTranscript · FY2024 Q4 →
Show response

Pong attributed the increase to three tenants from prior M&A, describing it as conservatism with expected rent recapture.

What's the threshold for you where those shares or, you know, where your equity becomes a little more attractive than other options

Capital AllocationTranscript · FY2024 Q4 →
Show response

Roy emphasized buyback authorization is a volatility tool to be used leverage-neutral with free cash flow and disposition proceeds.

DOCHealthpeak Properties7 questions · 4 reporting periods · 0 of 7 challenging
DOC company page →

Calendar 2026 Q2

are we getting back into an environment, where the distressed lab opportunity is looking more attractive to you?

M&ACompetitive DynamicsTranscript · FY2026 Q2 →
Show response

Brinker said the sector-recovery building blocks are in place and Healthpeak expects to be a consolidator over the next 24 months, citing Gateway leasing progress.

Calendar 2025 Q3

there's been tariffs on branded therapies, but there's also been a major surge in commitments by multinational pharma companies back in the U.S.

Regulation PolicyDemandTranscript · FY2025 Q3 →
Show response

Brinker cited Pfizer and AstraZeneca agreements as changing sentiment. Regulatory chaos of first 6-8 months subsiding with fewer negative headlines.

I don't know if we can discuss maybe the building blocks for '26 earnings here, especially as you have talked about a potential near-term bottoming in occupancy

Guidance ReliabilityTranscript · FY2025 Q3 →
Show response

Brinker deferred full guidance to February. Flagged purchase options, seller financing, and refinancing as additional building blocks. No new surprises.

Calendar 2025 Q1

Were the share repurchases driven by the relative attractiveness of the stock or is that more due to the difficulty of underwriting lab here?

Capital AllocationTranscript · FY2025 Q1 →
Show response

Brinker emphasized stock buybacks at ~10% FFO yield were driven by attractive valuation, not inability to deploy elsewhere.

in terms of underwriting Lab in an environment like this, how has it changed for you in terms of what you need to see maybe pre and post Liberation Day?

Capex InvestmentRegulation PolicyTranscript · FY2025 Q1 →
Show response

Brinker said rates haven't changed materially but lease-up timelines are extended. Bohn clarified it's more NIH/FDA uncertainty than tariffs.

Calendar 2024 Q4

at what availability rates do you expect to start getting pricing power back, even if you kind of adjust for maybe some of that noncompetitive supply?

PricingCompetitive DynamicsTranscript · FY2024 Q4 →
Show response

Pete Scott noted pricing power already emerging in their portfolio at mid-high 80% occupancy, aided by existing tenant relationships and campus scale.

it would be helpful if you could remind us of what kind of exposure you have to NIH funding, given it was -- there was just a temporary hold put on the funding block

Show response

Brinker noted no direct NIH exposure. Administration's focus on innovation and deregulation viewed positively. CMS/FDA leadership appointments more important than RFK.

WELLWelltower5 questions · 5 reporting periods · 0 of 5 challenging
WELL company page →

Calendar 2026 Q2

what constitutes the rest of that pie of sellers and also what’s driving this acceleration in transaction activity

M&ACompetitive DynamicsTranscript · FY2026 Q2 →
Show response

Chaudhri described data-driven off-market sourcing and Mitra added the generational-transfer dynamic across all three countries.

Calendar 2026 Q1

could you talk more about the growth of the talent density and the data science platform given what you described as a halo sector

Innovation & R&DCloud & AITranscript · FY2026 Q1 →
Show response

Mitra described strong inbound interest from real estate companies, banks, sovereign wealth funds following Public Storage partnership announcement. Hiring PhD talent from top quant funds and intelligence agencies due to senior housing's 'halo' status as AI-resistant sector.

Calendar 2025 Q4

what challenges are there left in the senior housing space to tackle?

Innovation & R&DCompetitive DynamicsTranscript · FY2025 Q4 →
Show response

Shankh described data science platform as mature but operational technology as early stage; firmly stated operating software will never be sold to competitors, only monetized through fund economics.

Calendar 2025 Q2

it sounds like your views are evolving with an opportunity to apply the operating technology to improve the customer experience. Could you elaborate

Innovation & R&DMarginTranscript · FY2025 Q2 →
Show response

Shankh described expanding technology focus from data science to enterprise and site-level tech integration, with significant changes expected in 6-9 months.

Calendar 2025 Q1

Would you mind walking us through the process in a bit more detail? And then also maybe giving some color around what percentage of your pipeline

Innovation & R&DM&ATranscript · FY2025 Q1 →
Show response

Shankh detailed how data science reduces deal latency from 5-10 months to 45-60 days, creating a first-call advantage with sellers.

VICIVici Properties2 questions · 1 reporting period · 0 of 2 challenging
VICI company page →

Calendar 2024 Q4

could you specify specifically maybe what types of real estate you'd be looking to own here?

M&ACapital AllocationTranscript · FY2024 Q4 →
Show response

CEO clarified One Beverly Hills won't become owned real estate but cited Chelsea Piers-type assets across Cain/Eldridge portfolio as fitting their net lease criteria.

how has the competitive landscape changed? I feel like across most of our earnings discussions this quarter, we've heard competition has certainly spiked

Competitive DynamicsTranscript · FY2024 Q4 →
Show response

COO stated competition has always been present and VICI differentiates through deep relationships rather than seeing an incremental spike.

Challenge rate by company

Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.

CompanyQuestionsChallenge rate
VTR Ventas922%2 of 9 questions
O Realty Income825%2 of 8 questions
DOC Healthpeak Properties70%none of 7 questions
WELL Welltower50%none of 5 questions
VICI Vici Properties2—Rate withheld: fewer than 3 questions
  • VTR
    Ventas · 9 questions
    22%2 of 9 questions
  • O
    Realty Income · 8 questions
    25%2 of 8 questions
  • DOC
    Healthpeak Properties · 7 questions
    0%none of 7 questions
  • WELL
    Welltower · 5 questions
    0%none of 5 questions
  • VICI
    Vici Properties · 2 questions
    —rate withheld: under 3 questions

Activity by reporting period

Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.

Questions by calendar reporting period
Calendar periodQuestionsChallenge rateCompanies
2024 Q4813%1 of 8 questions4
2025 Q1425%1 of 4 questions3
2025 Q250%none of 5 questions3
2025 Q3617%1 of 6 questions3
2025 Q4520%1 of 5 questions3
2026 Q110%none of 1 question1
2026 Q220%none of 2 questions2
  1. 2024 Q48 questions · challenge rate 13% (1 of 8 questions) · 4 companies
  2. 2025 Q14 questions · challenge rate 25% (1 of 4 questions) · 3 companies
  3. 2025 Q25 questions · challenge rate 0% (none of 5 questions) · 3 companies
  4. 2025 Q36 questions · challenge rate 17% (1 of 6 questions) · 3 companies
  5. 2025 Q45 questions · challenge rate 20% (1 of 5 questions) · 3 companies
  6. 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
  7. 2026 Q22 questions · challenge rate 0% (none of 2 questions) · 2 companies

Topics

Topics tagged on this analyst’s questions.

  • Competitive Dynamics9
  • M&A8
  • Capital Allocation7
  • Innovation & R&D5
  • Guidance Reliability4
  • Pricing4
  • Margin4
  • Regulation Policy3
  • Credit3
  • Demand2
Show all 15 topics
  • Cloud & AI1
  • Revenue Growth1
  • Geographic Expansion1
  • Capex Investment1
  • Cost Pressure1